Brief: Enlivex Therapeutics Reaffirms August 18, 2025 As Target Date For Announcement Of Phase II Topline Data
28/07/2025 13:40
July 28 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA: ENLIVEX REAFFIRMS AUGUST 18, 2025 AS TARGET DATE FOR ANNOUNCEMENT OF PHASE II TOPLINE DATA Source text: ID:nGNX9f0pdv Further company coverage: ENLV.TA (Reporting by Anshi Sancheti) ((Anshi.Sancheti@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment